Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059927 | 0.85 | KDM4E (0.43) | MAPTHPGDKDM4EALDH1A1CYP1A2 | |
| SCHEMBL14883627 | 0.81 | KDM4E (0.42) | MAPTLMNAKMT2AMAPK14HPGD | |
| SCHEMBL13635445 | 0.79 | CYP2C9 (0.44) | MAPTLMNAKMT2AHPGDKDM4E | |
| SCHEMBL10059948 | 0.78 | ALDH1A1 (0.53) | MAPTLMNAKMT2AMAPK14HPGD | |
| SCHEMBL14883620 | 0.76 | TNKS (0.46) | MAPTLMNAKMT2AMAPK14HPGD | |
| SCHEMBL14883623 | 0.75 | TNKS2 (0.47) | MAPTLMNAKMT2AHPGDKDM4E | |
| SCHEMBL10059939 | 0.75 | IDH1 (0.44) | MAPTLMNAKMT2AHPGDKDM4E | |
| SCHEMBL13635428 | 0.74 | KDR (0.48) | MAPTLMNAKMT2AMAPK14HPGD | |
| SCHEMBL13635444 | 0.74 | ALDH1A1 (0.45) | MAPTLMNAKMT2AMAPK14HPGD | |
| SCHEMBL14883635 | 0.74 | ALDH1A1 (0.45) | MAPTLMNAKMT2AMAPK14HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | UNIVERSITY OF MINNESOTA (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110218515-A1 | Methods for Treating Acute Myocardial Infarctions and Associated Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | MAPT 3360/4885LMNA 2852/4885KMT2A 4403/4885 |
| US-20120014917-A1 | METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS | MMP1, MMP8, CCL11 | MAPT 3357/4885LMNA 2124/4885KMT2A 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.